Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients

被引：0
作者：
Bijal Shah
Jenny M. H. Chen
James J. Wu
Chaoling Feng
Lang Zhou
Julie E. Park
Tsveta Hadjiivassileva
Fabio R. Kerbauy
Sally W. Wade
Sam Keeping
机构：
[1] Moffitt Cancer Center,
[2] PRECISIONheor,undefined
[3] Kite,undefined
[4] a Gilead Company,undefined
[5] Federal University of Sao Paulo and Beneficência Portuguesa de São Paulo,undefined
[6] Wade Outcomes Research & Consulting,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Acute lymphoblastic leukemia; Chemotherapy; Blinatumomab; Brexucabtagene autoleucel; Brexu-cel; Indirect comparison; Inotuzumab ozogamicin; KTE-X19; MAIC; Standard of care;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5383 / 5398
页数：15
相关论文
共 81 条
  • [1] Pulte D(2014)Survival of adults with acute lymphoblastic leukemia in Germany and the United States PLoS ONE 9 v69-v82
  • [2] Jansen L(2016)Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 27 166-175
  • [3] Gondos A(2019)Treatment of relapsed/refractory acute lymphoblastic leukemia Clin Adv Hematol Oncol 17 5568-5574
  • [4] Katalinic A(2010)Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration Cancer 116 11-22
  • [5] Barnes B(2021)KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results Blood 138 170-2160
  • [6] Ressing M(2022)Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study J Hematol Oncol 15 2147-961
  • [7] Hoelzer D(2019)Indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia Adv Ther 36 950-502
  • [8] Bassan R(2019)Matching-adjusted indirect comparison of blinatumomab vs. inotuzumab ozogamicin for adults with relapsed/refractory acute lymphoblastic leukemia Adv Ther 36 491-2487
  • [9] Dombret H(2021)KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Lancet (London, England) 398 2474-847
  • [10] Fielding A(2019)Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study Cancer 125 836-211
123456789